Navigation Links
OPAXIO(TM) Phase II Trial in Esophageal Cancer to be Presented in Proffered Session at the International Society of Gastrointestinal Oncology Annual Meeting
Date:9/23/2009

SEATTLE, Sept. 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that data from a Phase II study from Brown University of OPAXIO(TM) (paclitaxel poliglumex) combined with standard cisplatin and concurrent radiation in patients with advanced esophageal cancer will be presented by Dr. Howard Safran in an oral Proffered Papers session at the Annual Meeting of the International Society of Gastrointestinal Oncology in Philadelphia, Pennsylvania on Thursday, October 1st at 2:35 p.m. (Eastern time).

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    F: 206.272.4434
    E: deramian@ctiseattle.com
    www.celltherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.272.4345
    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.celltherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer
2. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
3. Complete Study Results Comparing CTIs OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
4. Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer
5. Oxygen Biotherapeutics, Inc. Receives Phase II Trial Approval in Israel
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
8. ANAVEX completes scale-up manufacturing of ANAVEX 2-73 for Phase I Alzheimers disease clinical trials
9. Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases
10. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
11. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... WAYNE, Pa. , May 4, 2017 /PRNewswire/ ... made from thermoplastics and other highly-engineered materials, is ... Microextrusion tubing has been developed in recent ... neurovascular interventional therapies and surgical applications. More expensive ... used to produce microextrusion tubing due to their ...
(Date:5/3/2017)... Calif. , May 3, 2017 ... of any hospital or healthcare facility. Commonly referred ... room is equipped with diagnostic imaging technology to ... of the heart. In these spaces, a team ... catheterization, balloon angioplasty, percutaneous coronary intervention, congenital heart ...
(Date:5/3/2017)... N.J. , May 3, 2017  Getinge, ... that contribute to quality enhancement and cost efficiency ... from a study of contemporary practice demonstrating that ... first-line therapy for critically ill patients. The single-center, ... Company,s newer large volume MEGA ® 50cc ...
Breaking Medicine Technology:
(Date:5/27/2017)... ... ... From May 21-23, hearing healthcare professionals gained a competitive edge with training from ... Downtown Hotel in Syracuse, New York. , As EarQ’s technology partner, Oticon hosts ... help them stay ahead in the industry. At the event, EarQ members learned about ...
(Date:5/26/2017)... ... 2017 , ... Leading CEOs from biotech, pharmaceutical, and healthcare ... at The Four Seasons Hotel Boston. , The Boston CEO Conference is ... access to key decision makers who influence deal making and investment. Attendees gain ...
(Date:5/26/2017)... , ... May 26, 2017 , ... A new analysis ... with the healthiest seniors are located in the Midwest. With the average cost of ... more people are concerned with both the quality and affordability of where they live. ...
(Date:5/26/2017)... Germantown, MD (PRWEB) , ... May 26, 2017 , ... ... the anti-stress Antzy Top gadget will continue to be available at a discounted crowdfunding ... people deal with stress wherever they are, I also wanted to bring a fidget ...
(Date:5/26/2017)... ... ... Dr. Alex Rabinovich, a highly-skilled oral surgeon specializing in wisdom teeth extraction ... options. If a Bay Area patient has to search for a second opinion before ... in-network provider for a second opinion can ensure a patient receives the full benefits ...
Breaking Medicine News(10 mins):